Thrombospondin with fibrinogen, fibronectin, and von Willebrand factor binds to platelets stimulated with agonists and support platelet adhesive functions. The receptors for the latter three proteins are associated with membrane glycoprotein GPIIIb-Ia. Thrombasthenic platelets deficient in GPIIb-IIIa have been utilized to examine the role of this membrane protein in the interactions of thrombospondin with platelets. Radioiodinated thrombospondin bound to thrombin-stimulated platelets from normal and thrombasthenic donors with a similar affinity and capacity. As monitored with a monoclonal antibody to thrombospondin, the divalent ion-dependent and -independent pathways for the expression of the endogenous pool of thrombospondin on the-surface of thrombin-stimulated platelets from normal and thrombasthenic donors were also qualitatively and quantitatively similar. GPIIb-IIIa or ligands associated with GPII-IIIa thus are not essential for the binding of thrombospondin to platelets. Therefore, thrombospondin interacts with unique receptors on platelets.
Introduction
Fibrinogen (Fg),' fibronectin (Fn), and von Willebrand factor (vWF) are large, multimeric glycoproteins that regulate platelet adhesive functions by interacting with specific receptors on the cell surface. Receptors for Fg, Fn, and vWF are not available on resting platelets but are rapidly induced by agonists such as thrombin (reviewed in ref. 1). A single platelet membrane glycoprotein, GPIIb-IIIa, is an obligate component ofthe inducible receptor for these adhesive proteins. The deficit in Fg (2, 3), Fn (4), and vWF (5) binding to thrombin-stimulated thrombasthenic platelets, which are genetically deficient in GPIIb-IIIa, was among the first evidence implicating GPIlb-IIIa as an inducible receptor for these adhesive proteins.
Thrombospondin (TSP) is a fourth platelet adhesive protein. This classification is suggested by its similarity in physiochemical properties to the other adhesive proteins (1, 6), by its capacity to agglutinate platelets and platelet membranes (7-9), and by the inhibition of platelet aggregation by polyclonal (10, I 1) and monoclonal antibodies (12) to TSP. TSP also interacts with a stimulus-induced set of saturable binding sites on platelets (13) .
Thrombin supports the binding of TSP to 35,100±9,600 sites/ platelet with a dissociation constant (Kd) of 250 nM (13) . Additional common properties of the interactions of TSP, Fg, Fn, and vWF with thrombin-stimulated platelets include a requirement for divalent ions and the inhibition of these interactions by Fg (13) and certain monoclonal antibodies to GPIIb-IIIa (13, 14) . The inhibition of TSP binding by Fg and these antibody reagents suggests that GPIIb-IIIa, and more specifically, Fg bound to or the Fg receptor on GPIIb-IIIa, directly mediates or is proximal to the TSP binding site. The interaction ofTSP with platelets is distinct from that ofthe other adhesive proteins in two respects. Firstly, TSP also binds to a second set of sites available on resting platelets (Kd, 50 nM; 3,100±1,000 molecules/platelet) in a divalent ion independent reaction (13) . Secondly, in contrast to Fg, Fn, and vWF, plasma does not constitute a significant source of TSP. Therefore, the predominant mechanism for surface expression of TSP is dependent upon secretion of TSP from its intracellular pool within a-granules (14) (15) (16) (17) .
In this study, the role of GPIIb-IIIa in the interactions of TSP with platelets has been examined. To assess this question, the binding of exogenous TSP to and the surface expression of endogenous TSP on thrombasthenic platelets deficient in GPIIbIlla has been analyzed. The results indicate that TSP interacts with a unique set of inducible receptors, independent ofGPIIbIIIa and Fg.
Methods
Platelets. Platelets were isolated by differential centrifugation followed by gel filtration on Sepharose 2B in divalent ion-free or calcium-free Tyrode's buffer, pH 7.3, containing 0.1-2% bovine serum albumin (13, 14, 17) . During the course of this study, two thrombasthenic patients were studied on three separate occasions. These thrombasthenic patients were made available by Dr. Margaret Johnson of the University of Delaware. Their deficit in adhesive protein binding and GPIIb-IIIa has been extensively documented in the literature (e.g., 2, 4, 18) while the levels of other membrane glycoproteins (GPI and GPIV) have been reported to be normal (19) . On two of the occasions, monoclonal antibodies to GPIIb-IIIa were used to verify the deficiency of the membrane glycoprotein. The deficit in GPIIb-IIla ranged from 85 to 87% as measured with the complex specific antibody AP2, kindly provided by Dr. Thomas Kunicki (20) , and 65-85% as measured with the GPIIb monoclonal antibody PMI-1 (21) . The platelet-rich plasma from the thrombasthenic patients as well as from a normal donor drawn in parallel were shipped at 22°C and analyzed within 24 h. Under these conditions, the binding of Fg, Fn, and vWF to freshly isolated and the shipped normal platelets were found to be very similar (4, 21, and unpublished observations).
Platelet binding and surface expression of TSP. TSP was isolated from fresh human platelets according to the method of Lawler et al. (22) with the modifications described from our laboratory (23) . The product was radioiodinated to specific activities of 0.5-1.0 AsCi/jg by a modified chloramine T procedure, and '25I-TSP ligands utilized in this study exhibited the characteristics previously described (13) . Varying concentrations of TSP ranging from 0.01 to 0.7 MM were added to nonstimulated or thrombin-stimulated (0.5-1.0 U thrombin/ml) platelets at 2 X 108/ ml (counted electronically in a Zf Coulter counter, Coulter Instruments, Inc., Hialeah, FL) in Tyrode's-albumin buffer containing the specified divalent ions. Binding was measured after a 30-min incubation at 370C
by centrifugation of triplicate 50-tl aliquots of the reaction mixtures through 20% sucrose (4, 13, 14) .
Surface expression of endogenous TSP was monitored using the monoclonal antibody TSPl-l (17). The antibody was purified from ascitic fluid on protein A Sepharose and radioiodinated to specific activities of -0.5 gCi/gg. Binding of '25I-TSPl-l to thrombin-stimulated platelets was measured by adding varying concentrations of the antibody in the 0.1-0.8-MM range to platelets at 2 X 108/ml. Conditions of these assays and for separation of cell-bound from free ligand were the same as for '251I-TSP, except that incubations were performed for 60 min at 220C (conditions optimal for maximal surface expression of TSP with the antibody reagent [17] ).
The data for the binding of 1251I-TSP and '251I-TSPl-l to the normal and thrombasthenic platelets were analyzed in the Ligand computer program (24) as previously described (13 
Results
The interaction of exogenously added TSP with thrombasthenic and normal platelets was compared. Varying concentrations of TSP were added to thrombin-stimulated platelets, and binding was measured after 30 min at 370C. The binding of TSP to the platelets from one of the two thrombasthenic patients is shown in Fig. 1 . The binding data provides evidence for saturable and high capacity binding of TSP to thrombasthenic platelets. Nonsaturable binding estimated in the Ligand program was 0.04% of the total TSP concentration added, and this value was used to derive the saturable binding curve shown in Fig. 1 . Similar analyses were performed with platelets from the second thrombasthenic patient and the normal donor drawn in parallel. The binding parameters obtained from Scatchard plots of the data have been summarized in Table I . The apparent dissociation constants, Kd, quantitated in this study for TSP binding to the two thrombasthenic patients and the normal donor are very similar and fall within the normal range (13) . In other experiments performed during the course of this study using normal platelets (n = 3), the Kd for TSP binding ranged from 200 to 500 nM and the number ofTSP binding sites ranged from 1 1,700 to 45,000. There is thus no deficit in the number or affinity of TSP binding sites on thrombin-stimulated thrombasthenic platelets.
TSP also interacts with saturable binding sites on nonstimulated platelets via a divalent ion-independent reaction. Although this interaction is unlikely to be dependent upon GPIIblIla based on the failure of Fg and monoclonal antibodies to GPIIb-IIIa to inhibit binding and the inappropriate stoichiometry between these TSP sites (3,000±1,000 sites/platelets [13] ) and GPIIb-IIIa ('-50,000 sites/platelet [20] ), direct verification of this conclusion was sought. '25I-TSP at 50 nM, its determined Kd for resting platelets (13) , was added to nonstimulated normal or thrombasthenic platelets, and binding was measured after a 30-min incubation at 370C in the presence of 5 mM EDTA. The number of TSP molecules bound per platelet was: 1,400 for thrombasthenic patient A; 3,300 for thrombasthenic patient B; and 1,700 for the normal donor. There is thus no deficit in the binding of TSP to nonstimulated as well as to thrombinstimulated thrombasthenic platelets.
Monoclonal antibody TSP I-I was used to monitor expression of the endogenous pool of TSP on the surface of thrombasthenic and normal platelets. As shown in Fig. 2 , TSP is expressed on the surface of thrombin-stimulated thrombasthenic 
